

CaNIOS Newsletter

VOL. 9 NO. 1

January 2009

www.CaNIOS.ca

New Hopes, New Dreams, New Beginnings
Happy New Year To All.

2009 CaNIOS PI Meeting Update

Our fundraising for our annual scientific meeting in April is moving along. We now have commitments from several of our industry supporters. Our Gold Sponsor this year is Bristol Myers Squibb. Amgen is our Silver Sponsor. Actelion, Abbott and UCB Pharma have agreed as Bronze Sponsors. We are also hoping to hear from other partners in the coming weeks.



Our meeting will be held at the Novotel Hotel in downtown Toronto on April 2 and 3, which will be followed by the Lupus Patient Symposium the following day. We will be sending the Registration Forms for the meeting by e-mail as soon as we get our scientific agenda finalized. Stay tuned.

Important Dates

Feb 18-21, 2009 – CRA Scientific Programme, Kananaskis, Alberta

April 2-3 2009 – CaNIOS Annual Meeting in Toronto

April 4, 2009 – 8th Annual Patient Symposium

May 9-10, 2009 – Walk-a-Block for Lupus 2009.

June 23-27, 2010 – International Lupus Congress, Vancouver, BC

INSIDE:

Abstracts submitted	p2
Papers submitted	p2
Manuscripts in preparation	p2
Recruitments	p3

Double Double

Plans are underway to hold our second Café Scientifique event during our an-

ual meeting in April. The topic is timely. **“Personalized Medicine:**

How will pharmacogenomics affect the way I manage my lupus?”

Latest 1000 Faces Publication

The manuscript by Peschken CA et al., entitled The 1000 Canadian Faces of Lupus: Determinants of

Disease Outcome in a Large Multi-Ethnic Cohort has been accepted for publication in the Journal of

Rheumatology. Way to go! and Congratulations to all.

CIHR Funding

CIHR has released the peer review results of our renewal applications for GenES Phase 2 and 2000 Faces of Lupus. CIHR did

not provide us funding this season, but we will continue to seek ways to fund these studies by sending another applications for the

spring competition. Expect requests for letters of collaborations in the coming weeks.

Walk-a-Block 2009

The date has been set for Walk-a Block For Lupus 2009. Save this date on your calendar - May 9 and 10, 2009. In the past 3

years, Toronto Western Hospital has organized a local Walk-A-Block Event in support of Lupus Canada's major fundraising event.

Please show you care by organizing your clinic's Walk-A-Block, or plan to join local events organized in your community.



CaNIOS Authorship Definition

To be a named author in any CaNIOS publication, one must meet conditions 1, 2, and 3 below:

- (1) Substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;
- (2) Drafting the article or revising it critically for important intellectual content; and
- (3) Final approval of the version to be published.

Manuscripts Submitted or Under Revision

Rheumatology (1000 Faces of Lupus)

Baker K, Pope J, Silverman E, Cooper G, Fortin PR, Zummer M, Smith CD, Petty, R, Tucker L, Albert L, Huber A, Ramsey S, Arbillaga H, Chedéville G, Hudson, M, CaNIOS Investigators; Peschken C. Work Disability in Systemic Lupus Erythematosus is Prevalent and Predicted by Socio-demographic and Disease Related Factors: Results from a Multi-Ethnic Cohort.

Journal of Rheumatology (1000 Faces of Lupus)

Lalani S, Peschken C, Pope J, CaNIOS 1000 Faces of Lupus Investigators. Clinical Features and Prognosis of Late Onset SLE.

In Press

Clinical Medicine: Arthritis and Musculoskeletal Disorders

Law G, Pope J, Lalani S, Silverman E, Cooper G, Fortin PR, Zummer M, Smith CD, Petty R, Tucker L, Albert L, Huber A, Ramsey S, Arbillaga A, Chedéville G, Hudson M, CaNIOS Investigators; Peschken, C. Barriers to Healthcare in a Multiethnic Cohort of Systemic Lupus Erythematosus (SLE) patients: Patient and Physician Perceptions.

Journal of Rheumatology (1000 Faces of Lupus)

Peschken CA, Katz S, Silverman E, Pope J, Fortin PR, Pineau C, Smith CD, Arbillaga H, Gladman D, Urowitz M, Zummer M, Clarke A, Bernatsky S, Hudson M, Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus (CaNIOS). The 1000 Canadian Faces of Lupus: Determinants of Disease Outcome in a Large Multi-Ethnic Cohort .

Submitted CRA Abstracts

B-Cell: Julie Kim, Ellie Aghdassi, Dafna Gladman, Murray Urowitz, Paul R. Fortin, and Joan Wither. Evidence for altered activation of newly-emergent bone marrow-derived B cells in Systemic Lupus Erythematosus (SLE).

ThomboFIL: Akhavan PS, Neville C, Su J, Kassis J, Solymoss S, Pineau C, Peschken C, Pope J, Boire G, Rauch J, Fortin PR. Vascular events in systemic lupus erythematosus (SLE): evaluation of thrombophilic factors in a multicentre inception cohort (ThromboFIL).

LuNNET: Aghdassi E, Morrison S, Landolt-Marticorena C, Su J, Pineau C, Pope J, Peschken C, Gladman D, Urowitz D, CaNIOS LuNNET Investigators, Wither J, and Fortin PR. Quality of life in lupus patients with and without renal involvement.

LuNNET: Adams K, Landolt-Marticorena C, Unnithan T, Gladman D, Urowitz M, Fortin PR, and Wither JE. Circulating levels of sVCAM, IP-10 and MCP-1 correlate with changes in disease activity in Systemic Lupus Erythematosus.

HIPP: Aghdassi E, Su J, Claudio J, Morrison S, Cymet A, Neville C, CaNIOS Investigators, Da Costa D, Fortin PR. The Use of Micronutrient Supplements among Patients with Systemic Lupus Erythematosus.

HIPP: Al Dhanhani AM, Harvey P, J Su, Cymet A, Harvey P, Da Costa D, Fortin PR. FMD measurement among lupus patients.

1000 Faces: Colangelo K, Pope J, Peschken C, and Members of 1000 Faces of Lupus. The minimally important difference for patient reported outcomes in SLE including pain, fatigue and SF36.

1000 Faces: Baker K, Pope J, Silverman E, Cooper G, Fortin PR, Zummer M, Smith CD, Petty, R, Tucker L, Albert L, Huber A, Ramsey S, Arbillaga H, Chedéville G, Hudson, M, CaNIOS Investigators; Peschken C. Work Disability in Systemic Lupus Erythematosus is Prevalent and Predicted by Socio-demographic and Disease Related Factors: Results from a Multi-Ethnic Cohort.

1000 Faces: Yuen SY, Mok MY, Wong WS, Pope J, Silverman E, Tucker L, Smith CD, Bernatsky S, Pineau C, Zummer M, Chedéville G, Urowitz M, Gladman D, Clarke A, Fortin PE, Peschken C. Systemic Lupus Erythematosus (SLE): A Comparative Study of Clinical Manifestations and Damage in Two Chinese Populations.

Manuscripts In Preparation (Contact senior author if you wish to be included as author.)

GenES Study : Serology Studies - Dr. Joan Wither;
Environmental Data (i.e., UV light and radiation) - Dr. Glinda Cooper
Analysis of Candidate Genes and SNPs - Drs. J Wither/Dr. PR Fortin/Dr J Rioux

LuNNET Study: BAFF Expression in Lupus - Drs. J Wither/PR Fortin
Gene expression from renal biopsies - Dr. H. Reich
Important Predictors of CKD - Dr. Heather Reich/ Paul R. Fortin

1000 Faces of Lupus Study: Pediatric Lupus - Dr. L. Tucker/Dr. C Peschken

1000 Faces of Lupus Study: The minimally important difference in SLE - Janet Pope

1000 Faces of Lupus Study: Predictors and Functional Impact of Lupus Lung Disease—Christine Peschken, Shikha Mittoo

CaNIOS STUDY ENROLLMENT

1000 Faces of Lupus – Enrolled = 1878

Centre 01 MUHC-MGH	294
Centre 04 Maisonneuve Rosemont	88
Centre 07 Ottawa Hospital	83
Centre 08 London	240
Centre 10 Winnipeg HSC	258
Centre 15 Vancouver ARC	22
Centre 17 TWH CPSRD	575
Centre 19 TWH Non-CPSRD	35
Centre 20 Sick Kids, Toronto	145
Centre 21 BC Children's Hosp.	61
Centre 22 Halifax's IWK HC	10
Centre 26 Lethbridge	26
Centre 27 Montreal Child. Hosp.	19
Centre 33 Jewish General Hosp.	22

HIPP – Randomized = 278

Centre 01 MGH	128
Centre 08 London	45
Centre 17 TWH-CPSRD	89
Centre 19 TWH-Non CPSRD	9
Centre 28 Mt. Sinai & Community	7

GenES Phase I (Recruitment Closed)

ThromboFIL (Recruitment Closed)

LuNNET Cohort 2 (Including 2B and 2C) = 48

Centre 17 TWH CPS	42	Cohort 2	n = 23
Centre 19 TWH non-CPS	5	Cohort 2B	n = 18
Centre 28 Mt. Sinai	1	Cohort 2C	n = 7
Total	48	Total	n = 48

LuNNET Cohort 3 (Prospective Cohort) = 119

Centre 01 MGH	11	Active SLE with Lupus Nephritis: n = 60 Active SLE with out Lupus Nephritis: n = 46 Non-active SLE with History of Lupus Nephritis: n = 32 Non-active SLE without History of Lupus Nephritis: n = 27 Unknown: n = 2
Centre 08 London	7	
Centre 10 Winnipeg	6	
Centre 17 TWH CPS	91	
Centre 19 TWH non-CPS	4	
Total	119	

Privacy

If you wish to be unsubscribed from the CaNIOS monthly newsletter e-mail list please contact Jaime O. Claudio, CaNIOS' National S&D Coordinator at:

Tel (416) 603-5800 ext. 3158; Fax: (416) 603-6288;

or e-mail: jclaudio@uhnresearch.ca.

Contact

CaNIOS Coordinating Centre
Toronto Western Hospital
399 Bathurst Street, MP 10-303
Toronto, ON M5T 2S8, Canada

Phone: 416-603-5800 extension 3158

Fax: 416-603-6288

e-mail: jclaudio@uhnresearch.ca

Web: www.CaNIOS.ca

About CaNIOS

CaNIOS is a unique collaboration that brings together widespread scientific and clinical expertise in a coordinated and collaborative spirit which allows Canadian researchers to address several questions important to patients with lupus and their families. Founded in 1995 when the current chair, Dr. Paul R. Fortin was at the Montreal General Hospital, CaNIOS Coordinating Centre moved to Toronto Western Hospital in 2000. CaNIOS maintains a database of lupus patients through its National Lupus Registry which combines data from different centres through a standardized data collection system. CaNIOS has been supported solely by funding from individual operating grants from governmental agencies and non-for-profit organizations and foundations.